The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IONS | +93.54% | +58.25% | +9.6% | +643% |
| S&P | +19.89% | +109.18% | +15.89% | +1,737% |
Ionis Pharmaceuticals is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $156.72M | 17.1% |
| Gross Profit | $151.51M | 19.1% |
| Gross Margin | 96.67% | 1.6% |
| Market Cap | $10.43B | 65.0% |
| Market Cap / Employee | $9.75M | 0.0% |
| Employees | 1.1K | 15.3% |
| Net Income | -$128.61M | 8.5% |
| EBITDA | -$155.68M | -8.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $338.34M | 1.1% |
| Accounts Receivable | $24.61M | 37.3% |
| Inventory | 10.5 | -63.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.40B | -27.7% |
| Short Term Debt | $644.89M | 1350.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -8.37% | 3.5% |
| Return On Invested Capital | -16.33% | -6.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$136.71M | -10.2% |
| Operating Free Cash Flow | -$131.44M | -14.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.33 | 8.10 | 13.21 | 16.49 | 72.75% |
| Price to Sales | 7.83 | 6.67 | 7.63 | 10.80 | 45.85% |
| Price to Tangible Book Value | 8.33 | 8.10 | 13.21 | 16.49 | 72.75% |
| Enterprise Value to EBITDA | -49.45 | -32.51 | 47.40 | -65.89 | 72.94% |
| Return on Equity | -93.0% | -118.5% | -59.8% | -40.0% | -45.47% |
| Total Debt | $1.96B | $1.96B | $1.97B | $2.05B | 3.22% |
The failed attempt to repeal and replace Obamacare last month has big implications for healthcare investors.
Merck, Gilead Sciences, and Ionis get a verdict in their patent suit, and Congress calls for a patent review of Medivation's Xtandi.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
